Immunic announces publication of extended data from phase 2 emphasis trial of vidofludimus calcium in relapsing-remitting multiple sclerosis in the peer reviewed journal, neurology® neuroimmunology & neuroinflammation
– 30 mg and 45 mg daily doses of vidofludimus calcium suppressed development of gadolinium-enhancing lesions by 78% and 74% compared to pooled placebo at 24 weeks – – improvements in serum neurofilament light chain consistent with recently announced interim phase 2 calliper data in progressive multiple sclerosis – – twin phase 3 ensure trials in relapsing multiple sclerosis and phase 2 calliper trial in progressive multiple sclerosis remain underway – new york , april 30, 2024 /prnewswire/ -- immunic, inc. (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that data from its phase 2 emphasis trial of lead asset, vidofludimus calcium (imu-838), in patients with relapsing-remitting multiple sclerosis (rrms) has been published online on april 25, 2024 in neurology® neuroimmunology & neuroinflammation, an official journal of the american academy of neurology. the paper, lead authored by coordinating investigator, robert j.
IMUX Ratings Summary
IMUX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission